Solid Tumor - fulzerasib - KRAS G12C

Association details:

Biomarker:	KRAS G12C
Cancer:	Solid Tumor
Drug:	Dupert (fulzerasib) (KRAS G12C inhibitor)
Direction:	Sensitive

Evidence:

Evidence Level:

Sensitive: C2 – Inclusion Criteria

Source:

clinicaltrials.gov

Title:

A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation

Excerpt:

...Have histologically or cytologically confirmed advanced KRAS G12C-mutated NSCLC....

Trial ID:

NCT05756153

Evidence Level:

Sensitive: C2 – Inclusion Criteria

Source:

clinicaltrials.gov

Title:

A Study of GFH925 in Patients With Advanced Solid Tumors With KRAS G12C Mutations

Excerpt:

...- Pathologically diagnosed, previously treated, advanced tumor with KRAS p.G12C mutation...

Trial ID:

NCT05005234

More C2 evidence

Evidence Level:

Sensitive: C2 – Inclusion Criteria

Source:

clinicaltrials.gov

Title:

A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer

Excerpt:

...have documentation of KRAS G12C mutation 3....

Trial ID:

NCT05497336

Evidence Level:

Sensitive: C2 – Inclusion Criteria

Source:

clinicaltrialsregister.eu

Title:

An open, multicentre, phase I/II study to evaluate the effectiveness and safety of IBI351 combined with platinum-containing chemotherapy and ⻉vazumab in subjects of KRAS G12C mutation or metastatic non-squamous non-small cell lung cancer subjects

Excerpt:

...1.Volunteer to participate in the research and sign the informed consent form; 2.≥18 years old and ≤75 years old when signing the informed consent form; 3.Expected survival time ≥3 months; 4.According to the 9th edition of the International Association for Lung Cancer Research and the Joint Commission for the Classification of Cancer in the United States, lung cancer TNM stage, locally advanced (phase III B/III C), metastatic or recurrent (phase IV) non-scale NSCLC subjects who cannot be surgically removed and cannot be subjected to radical synchronous radiotherapy confirmed by histology or cytology; 5.There is a clear test report proving that there is a mutation of KRAS G12C. ...

Trial ID:

ChiCTR2400090974

Evidence Level:

Sensitive: C3 – Early Trials

Source:

ASCO 2022

Title:

Phase I dose-escalation study of IBI351 (GFH925) monotherapy in patients with advanced solid tumors.

Published date:

05/26/2022

Excerpt:

IBI351(GFH925) was well-tolerated without unanticipated adverse events across all doses explored in pts with advanced solid tumors harboring the KRAS p.G12C mutation.

Trial ID:

NCT05005234